Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
35,675,307
-
Share change
-
+6,182,817
-
Total reported value
-
$1,103,430,422
-
Put/Call ratio
-
97%
-
Price per share
-
$30.93
-
Number of holders
-
117
-
Value change
-
+$207,367,870
-
Number of buys
-
81
-
Number of sells
-
24
Institutional Holders of TCR2 THERAPEUTICS INC - COM (TCRR) as of Q4 2020
As of 31 Dec 2020,
TCR2 THERAPEUTICS INC - COM (TCRR) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,675,307 shares.
The largest 10 holders included
MPM ASSET MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, MPM Oncology Impact Management LP, MPM ONCOLOGY IMPACT MANAGEMENT, L.P., Redmile Group, LLC, BlackRock Inc., ArrowMark Colorado Holdings LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, and Marshall Wace North America L.P..
This page lists
117
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.